Pfizer is cutting costs, growing its core business, and trading at a deep discount despite looming patent losses and COVID ...

Roche’s move came against a backdrop of wider industry retreat from gene therapy, with Pfizer pulling its FDA-approved ...

Wrapping up Q1 earnings, we look at the numbers and key takeaways for the branded pharmaceuticals stocks, including Supernus ...

AbbVie just dropped an update on its Phase 3 clinical study. They're testing Lutikizumab, a potential treatment for ...

J.W. Cole Advisors Inc. significantly reduced its holdings in Amgen Inc., selling 4,695 shares, which resulted in a 28.9% ...